Advancing Surgical Precision: Jung Foundation Honors Pioneering Medical Research
On May 21, 2026, the Hamburg-based Jung Foundation for Science and Research announced the recipients of its prestigious medical awards. This year’s honors recognize three distinguished scientists for their groundbreaking work in pain research, oncology and the molecular mechanisms of rare diseases. These awards, totaling over 500,000 euros, underscore the foundation’s long-standing commitment to fostering excellence in human medicine.
Recognizing Excellence in Medical Science
The Jung Foundation, which has been honoring top-tier research since 1967, presented the following awards to leaders in their respective fields:
- Jung Prize for Medicine 2026: Awarded to Professor Rohini Kuner, a pharmacologist at the University of Heidelberg, who received 300,000 euros for her pioneering work in pain research. Her studies focus on neuronal plasticity, exploring how the nervous system structurally and functionally adapts to persistent stimuli, which in turn leads to the development of chronic pain.
- Jung Career Advancement Award 2026: Bestowed upon Dr. Fiona Kolbinger, a physician and researcher at the Carl Gustav Carus University Hospital, TU Dresden. Dr. Kolbinger received 210,000 euros for her innovative research at the intersection of surgery, data science, and artificial intelligence, specifically regarding its application in cancer surgery.
- Jung Medal for Medicine in Gold 2026: Awarded to molecular biologist Professor Taroh Kinoshita from the University of Osaka for his significant contributions to the diagnostics of rare diseases.
AI and the Future of Cancer Surgery
Dr. Fiona Kolbinger’s work, which earned her the Jung Career Advancement Award, centers on the integration of artificial intelligence to improve outcomes in oncological surgery. By analyzing data from past procedures, her research aims to identify the underlying reasons why certain surgeries succeed while others face complications. Her goal is to develop more precise, safer, and more tolerable treatment pathways for patients undergoing complex cancer operations.
This interdisciplinary approach aligns with the broader goals of the 6th Jung Symposium, “Excellence in Human Medicine 2026,” held at the University Medical Center Hamburg-Eppendorf. The symposium serves as a platform for these researchers to share findings that open new therapeutic avenues for serious, often difficult-to-treat conditions.
Key Takeaways
- Interdisciplinary Innovation: The 2026 awardees highlight the necessity of combining pharmacology, data science, and molecular biology to solve complex medical challenges.
- Focus on Patient Outcomes: From chronic pain management to AI-enhanced surgical precision, the awarded research is fundamentally aimed at clinical application and improved patient quality of life.
- Commitment to Research: Through substantial financial support, the Jung Foundation continues to empower scientists whose work challenges existing medical paradigms.
Looking Ahead
The findings presented by Professor Kuner, Dr. Kolbinger, and Professor Kinoshita represent the next generation of medical advancement. As the medical community continues to embrace digital tools and molecular insights, the work of these researchers provides a roadmap for more effective, personalized treatment strategies. By bridging the gap between fundamental research and clinical practice, these scientists are ensuring that the future of medicine remains focused on precision, safety, and patient-centered care.
Related reading